Augustine Therapeutics Funding: $104M Raised, Series A
Augustine Therapeutics is based in Leuven, Belgium. It has raised $104M in total funding. Latest round: Series A.
Augustine Therapeutics funding overview
Augustine Therapeutics is based in Leuven, Belgium. Augustine Therapeutics has raised $104M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in March 2025. The round record for Augustine Therapeutics runs through 2025; nothing later has been disclosed. Investors on record include Novo Holdings, Jeito Capital, Asabys Partners, Eli Lilly and Company, AdBio partners, V-Bio Ventures and 5 others. 11 distinct backers are named across the disclosed rounds.
Augustine Therapeutics at a glance
Total raised
$104M
Latest round
Series A
Latest round date
March 2025
Headquarters
Leuven, Belgium
Notable investors
Novo Holdings, Jeito Capital, Asabys Partners, Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB
Frequently asked about Augustine Therapeutics funding
How much has Augustine Therapeutics raised?
Augustine Therapeutics has raised $104M in total disclosed funding across the rounds on record.
Who has invested in Augustine Therapeutics?
Novo Holdings, Jeito Capital, Asabys Partners, Eli Lilly and Company, AdBio partners, V-Bio Ventures are named among the investors backing Augustine Therapeutics.
What was the latest Augustine Therapeutics funding round?
The most recent disclosed round is a Series A, announced in March 2025.
Where is Augustine Therapeutics based?
Augustine Therapeutics is based in Leuven, Belgium.
When did Augustine Therapeutics last raise?
The last disclosed Augustine Therapeutics round closed in March 2025 at Series A.
Augustine Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Leuven below to benchmark round size and investor mix.
